ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Severe community-acquired pneumonia.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Pooled it
- Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- The effect and safety of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis of randomized controlled trials.Frontiers in medicine · 2024Pooled it
- Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Impact of high-protein enteral nutrition on muscle preservation in mechanically ventilated patients with severe pneumonia: a randomized controlled trial.Journal of health, population, and nutrition · 2024Trial
- The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial.Critical care (London, England) · 2023Trial
- Phenotype-based appropriateness of IGM-enriched polyclonal immunoglobulin use in critical illness: report of an expert consensus.Journal of anesthesia, analgesia and critical care · 2026Review
- Performance and Validation of a New Long-Term Mortality Risk Score in Community-Acquired Pneumonia: A Colombian Cohort.Infectious disease reports · 2026Article
- Risk of pneumonia in adults with chronic cough: a nationwide cohort study.BMJ open respiratory research · 2026Article
- Incremental prognostic value of the systemic immune‑inflammation index, pan‑immune‑inflammation value, and modified glasgow prognostic score for severity assessment and outcome prediction in community‑acquired pneumonia.BMC pulmonary medicine · 2026Article
- Comprehensive analysis of factors to consider when using glucocorticoids for sCAP: A review.Medicine · 2026Review
- An interpretable radiomics-machine learning model for early risk stratification of invasive fungal infections in community-acquired pneumonia: a dual-center study.Scientific reports · 2026Article
- Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia in the intensive care unit.Journal of thoracic disease · 2026Article
- Dynamic Parameters within the First 72 H of ICU Admission Predict Extubation Failure and 28-Day Mortality in Severe Pneumonia-Induced ARDS: A Retrospective Cohort Study.The clinical respiratory journal · 2026Article
- Fluorescence-based index from the SofiaMicrobiology spectrum · 2026Article
- A combined model based on lactate clearance rate and SOFA score in prognostic assessment of patients with severe pneumonia.BMC immunology · 2026Article
- The impact of the timing of mNGS-guided antibiotic adjustment on clinical outcomes in ICU patients with severe community-acquired pneumonia: a retrospective study.Annals of clinical microbiology and antimicrobials · 2026Article
- Serum inflammatory markers nt-probnp, hs-crp and il-6 predict disease severity and mortality in severe community-acquired pneumonia: A propensity score matching study.Journal of medical biochemistry · 2026Article
- Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia.BMC public health · 2026Article
- Development and validation of machine learning-based prediction for in-hospital mortality in ICU patients with severe community-acquired pneumonia and respiratory failure.Frontiers in medicine · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe community-acquired pneumonia is the most life-threatening form of community-acquired pneumonia, characterised by intensive care unit admission and high morbidity and mortality. In this review article, we cover in depth six aspects of severe community-acquired pneumonia that are still controversial: use of PCR molecular techniques for microbial diagnosis; the role of biomarkers for initial management; duration of treatment, macrolides or quinolones in the initial empirical antibiotic therapy; the use of prediction scores for drug-resistant pathogens to modify initial empiric therapy; the use of noninvasive mechanical ventilation and high-flow nasal oxygen; and the use of corticosteroids as adjunctive therapy in severe community-acquired pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.